Board of Directors
Company Risk
The proportion of revenue that the Company received through coordinators/referrals in 2022, 2023, 2024, and 2025 was 93.46%, 76.61%, 84.78% and 91.16 respectively.
The Company has expanded its network of coordinators and referral partners to mitigate the risk associated with reliance on any single coordinator or referral partner, while also increasing opportunities to broaden its customer base. As of the end of 2022, 2023, 2024, and 2025, the Company had 5, 15, 10, and 23 coordinators and referral partners, respectively. In addition, the Company has implemented strategies to expand revenue generated from direct customer engagement through both domestic and international marketing initiatives. These efforts include marketing through the Company’s online platforms as well as organizing service introduction activities at the clinic. Such initiatives aim to increase the proportion of revenue derived from direct customer contacts.
The Company has complied with all applicable laws and regulations and has obtained all necessary licenses and certifications in full, covering both infertility treatment services and preventive and rehabilitative medical services. In addition, the Company has designated responsible personnel to monitor laws, regulations, and relevant regulatory requirements applicable to its business. This ensures that the Company is able to prepare for and comply with such requirements accurately and within the prescribed timeframes.
To manage risks related to legal and regulatory compliance, the Company has implemented the following measures: Compliance with Laws and Regulations The Company has obtained all relevant licenses and certifications in full, covering both infertility treatment services and preventive and rehabilitative medical services. Designation of Responsible Personnel The Company has appointed designated personnel responsible for monitoring and reviewing applicable laws, regulations, and regulatory requirements relevant to its business. This ensures that compliance actions are carried out accurately and within the prescribed timelines. Ongoing Monitoring and Review The Company has established processes for the continuous monitoring and regular review of regulatory requirements relevant to its business. This enables the Company to remain prepared and to adjust its operations in line with changes in applicable laws and standards. The Company operates in accordance with standards applicable to medical assisted reproductive technology, as stipulated under the Protection of Children Born through Assisted Reproductive Technologies Act B.E. 2558 (2015), as well as requirements issued by relevant government authorities.
The provision of services to each customer involves specific time-sensitive processes. If the Company lacks personnel in any particular area and is unable to recruit suitable replacements in a timely manner, this may result in an inability to carry out infertility treatment procedures within the required timeframe.
Recruitment and Development of Replacement Personnel The Company has established processes for the recruitment and development of personnel in key positions, such as training scientists in each functional area, to ensure continuity of operations. Preparation of Operating Manuals The Company has prepared operating manuals to enable personnel to perform their duties in a standardized manner, thereby reducing risks associated with reliance on specific individuals. Engagement of Part-Time Physicians The Company engages physicians on a part-time basis to accommodate an increase in the number of customers and to mitigate the risk of physician shortages. The Company manages appointment scheduling between customers and selected part-time physicians. Management of Preventive and Rehabilitative Medical Services The Company assigns full-time physicians to care for customers receiving infertility treatment services and provides one part-time physician for general customers. The Company also has plans to engage additional part-time physicians should demand for preventive and rehabilitative medical services increase in the future. Employee Retention and Incentives The Company has established appropriate and equitable compensation and benefits policies, while promoting personnel development, fostering corporate culture, and providing incentives to ensure that personnel understand and share the same vision and objectives, and are committed to supporting the Company’s sustainable growth.
Competition in the regenerative medicine business is expected to intensify, driven by government policies promoting health tourism. This has encouraged several operators in Thailand to enter the market, particularly in providing Double Filtration Plasmapheresis (DFPP), which is currently the Company’s core service in the regenerative medicine segment. In addition, a number of hospitals, wellness centers, and aesthetic clinics have also begun offering similar services.
Building Brand Awareness and Confidence in Quality The Company places strong emphasis on building brand awareness and continuously enhancing service quality to strengthen customer confidence. It is the first infertility treatment center in Asia to be accredited with both AACI and ISO 9001:2015 standards. Notably, AACI is the only international standard that certifies both International Healthcare Standards and ISO 9001 simultaneously. International Accreditation The Company has been accredited by Global Healthcare Accreditation as the second institution worldwide under the specialized Covid-19 Medical Travel Program. It has also received certification from Temos International Healthcare Accreditation in Germany for both Quality in Reproductive Care and Excellence in International Reproductive Care. Developing New Services for Differentiation The Company continues to introduce new services to customers, such as preventive and regenerative medicine, genetic testing using SNP array technology, and closed-system embryo culture with AI-based monitoring and scoring. These innovations enhance opportunities for successful pregnancies and reinforce customer confidence in the Company’s services. Market Positioning The Company positions itself within the mid- to high-end customer segment, with facilities located in Bangkok’s central business district. The premises are designed to reflect a premium brand image, and international customer service staff are available to cater to foreign clients who represent a key target group. Enhancing Competitiveness in Regenerative Medicine The Company believes that offering regenerative medicine services alongside infertility treatment strengthens its competitive advantage. Its established base of infertility treatment clients provides a significant foundation compared to operators offering only regenerative medicine services. This reflects the Company’s risk management approach through a Differentiation Strategy and Quality Assurance, ensuring sustainable competitive advantage in an industry that continues to grow and attract new entrants.
In the future, new treatment methods may be developed, some of which could involve incremental improvements to existing technologies to enhance their effectiveness—such as more advanced and safer medical instruments and equipment. Alternatively, entirely new technologies or treatment approaches may emerge. Such developments could have an impact on the Company’s business operations if it is unable to adapt promptly to these changes.
Monitoring Academic Information and Scientific Progress The Company has designated responsible personnel to monitor technological developments and academic publications relevant to the industry, ensuring that it remains up to date with medical and scientific advancements. Supporting Personnel Development The Company consistently encourages its staff to participate in medical conferences and seminars both domestically and internationally, thereby enhancing their knowledge and understanding of emerging treatment approaches. Investing in New Technologies The Company is prepared to invest in technologies that improve service efficiency, such as embryo chromosomal testing using SNP Array, four-dimensional ultrasound, and health management through DFPP equipment. Utilizing Advanced Technology and AI The Company has invested in closed-system embryo culture technology (Embryoscope Plus), which applies AI to monitor and evaluate embryo development, as well as semen analysis systems that employ AI to select and score sperm quality. Evaluating Economic Value The Company considers both customer benefits and economic value when making investment decisions, ensuring that its investments deliver quality outcomes while supporting long-term business sustainability.
Certain pharmaceutical products and medical supplies are distributed exclusively by a single foreign manufacturer. For example, the reagents used specifically with embryo genetic testing through SNP Array technology are proprietary to one overseas operator. In addition, some medicines and medical supplies possess unique characteristics that precisely meet the requirements of physicians or scientists, resulting in procurement being limited to specific distributors. If the Company is unable to procure these products in the required quantity or within the desired timeframe, it could directly affect the services provided to customers.
Establishing Alternative Supplier Lists The Company has prepared a list of suppliers that can provide substitute products for those currently used in its services, while also monitoring new alternative products that may become available, thereby creating additional procurement options. Managing Non-Substitutable Products For products that cannot be substituted, the Company maintains close coordination with distributors to ensure that procurement can be carried out in line with operational requirements. Assigning Responsibility for Inventory Control The Company has designated personnel responsible for monitoring inventory levels to ensure that stock remains sufficient but not excessive, thereby aligning inventory management with actual usage needs.
Medical services, including infertility treatment and plasma filtration using Double Filtration Plasmapheresis (DFPP), cannot guarantee success in every case. There is a possibility that customers may be dissatisfied with treatment outcomes or the services provided by the Company. In addition, there is a risk that customers may experience complications or abnormalities perceived to result from the Company’s medical services, which could lead to litigation and claims for damages. Such risks may adversely affect the Company’s image and reputation, as well as potentially impact its operating performance in the event of compensation claims.
Enhancing Service Quality Standards The Company places strong emphasis on service quality through internationally recognized standards, including AACI, ISO 9001:2015, Global Healthcare Accreditation (GHA), and Temos International Healthcare Accreditation, to build global confidence and ensure safety and assurance in treatment. Rigorous Personnel Selection The Company prioritizes the recruitment of experienced and specialized professionals, including physicians, embryologists, genetic screening scientists, nursing teams, and customer service staff with industry expertise. Comprehensive Communication and Information Disclosure Customer relations officers are skilled in coordination and multilingual communication, providing guidance and detailed service information, including potential risks. The Company follows a structured process of verbal explanation. It requires customers to sign informed consent forms in accordance with the Medical Council’s regulations, and clearly specifying the relevant laws and regulations. Medical Supervision For plasma filtration services using Double Filtration Plasmapheresis (DFPP), the Company requires medical supervision to assess suitability and closely monitor potential complications, particularly for patients with underlying conditions. Customer Satisfaction Monitoring Customer relations officers continuously monitor and evaluate customer satisfaction throughout the service process. Any cases of dissatisfaction or misunderstanding are reported to supervisors for corrective measures in line with Company policy. Professional Liability Insurance The Company maintains a policy of professional liability insurance for both full-time and part-time physicians to mitigate risks associated with potential litigation. Operational Track Record To date, the Company has never faced disputes or litigation arising from its medical services. This demonstrates the effectiveness of its risk management approach, which emphasizes prevention and trust-building strategies to minimize litigation risks while safeguarding the Company’s reputation, brand image, and operating performance. Quality Development The Company has continuously improved the quality of its services, with primary emphasis on the safety of patients receiving its services.
The Company engages physicians both as full-time employees and on a part-time basis, applying withholding tax according to the type of employment to ensure accurate and complete submission to the Revenue Department. However, the Revenue Department’s practices in assessing personal income tax for physicians may differ from the Company’s withholding tax approach. In the event of such discrepancies, the Company faces the risk of remitting withholding tax amounts that do not align with the actual tax obligations, which could result in additional tax liabilities or penalties and potentially affect the Company’s operating performance.
Establishing Written Agreements The Company has entered into written agreements with part-time personnel, requiring them to acknowledge and agree to bear any additional tax liabilities that may arise from the Revenue Department’s assessment, resulting from the Company’s withholding tax practices. Preventing Adverse Impacts on the Company These agreements are intended to safeguard the Company against potential impacts arising from differences in interpretation or assessment of tax obligations by the Revenue Department. Contractual & Tax Risk Prevention Strategy enables the Company to mitigate the risk of discrepancies in withholding tax remittance compared with the Revenue Department’s assessment and to maintain the Company’s financial stability.
Revenue and Operating Performance Revenue decreased significantly, resulting in the Company incurring losses in several years. Service Provision Operational limitations arose, particularly in providing services to foreign clients. Customer Confidence Uncertainty regarding travel to Thailand for services affected customers’ decision-making.
Measures during 2020–2021 (COVID-19) - The Company managed its business during the COVID-19 pandemic by shifting its target customer group from international clients to domestic clients. - This period was utilized to improve service quality and standards, thereby enhancing customer confidence. - The Company obtained international accreditations, including: - Global Healthcare Accreditation (COVID-19 Program for Medical Travel) - AACI for healthcare organizations - ISO 9001:2015 in 2021 - Marketing channels were adjusted by increasing online publicity to raise awareness among domestic clients and to maintain communication with international clients who were unable to travel. - The Company has also adjusted its business strategy by placing greater emphasis on expanding its domestic target customer segment. - Strict COVID-19 safety measures were implemented, such as temperature checks, health questionnaires, pre-service health screenings, social distancing, and mandatory mask-wearing at all times. Post-COVID-19 Measures - Although the impact of COVID-19 has diminished and international clients have resumed using services, the Company continues to monitor information regarding other epidemics that may affect the business. - Plans have been established to manage and mitigate potential future impacts. - There are investment or joint investment plans to expand branches abroad in order to diversify risks and reduce reliance on international clients who must travel to Thailand. Measures in 2025 (Civil Unrest and International Conflicts) - In response to civil unrest in India that led to airport closures, and conflicts between Thailand and neighboring countries that affected customer confidence, the Company implemented additional measures, including: - Diversifying the customer base: Increasing the proportion of domestic clients and expanding into other international markets to reduce reliance on clients from politically unstable or unrest-prone countries. - Developing alternative service channels: Such as telemedicine and online consultations to support clients unable to travel. - Establishing partnerships with international allies: Allowing clients to access services through partner networks in other regions. - Closely monitoring international situations: To assess impacts and promptly adjust operational strategies.
This risk may result in the Company being unable to renew its lease under the specified conditions or facing changes in terms that could affect costs and business continuity. Consequently, the Company is exposed to the risk of having to find new operating premises if the lease is not renewed, which may cause service disruptions for a certain period unless advance management measures are prepared. Nevertheless, at present, the Company is able to continue providing services at the same location as usual.
The Company’s service facilities comprise customer reception areas, examination rooms, operating rooms, an embryo laboratory (Embryo Lab), and a genetic laboratory (Genetic Lab). At present, the Company operates one service location at the Ploenchit Center Building, where Prime Office Leasehold Property Fund (“the Fund”) holds the leasehold rights to the land on which the building is situated. The Company’s current lease agreement for the premises will expire on June 30, 2027, while the land lease agreement between the Fund and the landowner will expire earlier, on January 23, 2025. This discrepancy poses a risk that the Company may be unable to renew its lease under the specified conditions or may face changes in terms that could affect costs and business continuity. Consequently, the Company is exposed to the risk of having to find new operating premises if the lease is not renewed, which may cause service disruptions for a certain period unless advance management measures are prepared. Nevertheless, at present, the Company is able to continue providing services at the same location as usual. The Fund and the landowner have jointly signed a notice of transfer of leasehold rights and building services for the Ploenchit Center with the Company, informing that all rights and obligations of the Fund as lessor and service provider will be transferred to the landowner upon the Fund’s land lease expiration. Accordingly, the Company retains the right to lease the premises until June 30, 2027, under the current lease agreement, which also provides the option for the tenant to request renewal. The agreement stipulates that the Company must notify its intention to renew the lease at least 180 days prior to expiration, and the lessor must respond within 90 days of such notice. This timeframe provides sufficient assurance for the Company to manage operations and ensure service continuity. Furthermore, the landowner has issued a letter confirming the intended use of the Ploenchit Center Building as office space and agreed that the Company may lease the premises for business operations until 2034. The Company has consistently complied with lease conditions and successfully renewed its lease agreements in the past. Therefore, the Company is confident that it will continue to receive lease renewals going forward. Nevertheless, the Company has investment or joint investment plans to expand branches or add service points both domestically and internationally. These initiatives will help reduce the risk of relying on a single operating location in the future.
If there is a change in the executive holding this position and the Company is unable to recruit a new executive with the necessary qualifications and suitability, it may result in difficulties for the Company in conducting its business in the future.
Establish a succession plan to address cases where the key executive is unable to perform duties. Develop personnel at various levels to ensure readiness to assume critical responsibilities in place of the executive. Implement clear and standardized working systems to ensure continuity of operations even in the event of changes in executive positions. Build a team with diverse capabilities and experiences to distribute responsibilities and reduce reliance on any single individual.
The Company is exposed to risks arising from the influence of major shareholders on policy formulation and management, as they hold a significant proportion of voting rights. This may result in important decisions of the Company being determined primarily by the views or interests of the major shareholders, which may not align with the interests of other shareholders or all stakeholders. Other shareholders may face the risk of being unable to gather sufficient votes to counterbalance matters proposed by the major shareholders. Such risks could affect the balance of policy formulation and the Company’s operations in the long term.
The Company has established a transparent and fair management structure, comprising personnel with knowledge and expertise, with clearly defined scopes of authority and responsibilities. A Nomination and Remuneration Committee has been established to select qualified individuals to support the Company’s growth and adapt to business changes appropriately. An Audit Committee has been appointed, consisting of three independent directors with no vested interests in the Company, to oversee operations and safeguard the interests of minority shareholders. These mechanisms help ensure an appropriate balance of power in management and provide sufficient oversight. The Company operates under the principles of Good Corporate Governance to ensure that management is transparent, fair, and aligned with the interests of all shareholders.
Shareholder Risk
The market price of the Company’s common shares and the demand for such shares may be volatile, which could result in the trading price on the Stock Exchange being significantly lower than the initial offering price. Such volatility may limit or prevent investors from selling the Company’s common shares as desired and may negatively affect the liquidity of the Company’s shares in the Stock Exchange.
The Company operates under the principles of Good Corporate Governance to promote transparency and confidence among security holders. Important information is disclosed fully and in a timely manner, enabling security holders to monitor and appropriately assess performance. The Company regularly prepares performance reports and risk reports to keep security holders informed of situations that may affect their investments. External factors such as economic conditions, capital markets, and market liquidity are monitored and assessed to prepare proactive measures. The Company promotes continuous communication with security holders to build understanding and confidence in investment.
Compliance with securities laws or other regulatory provisions in certain countries may restrict some investors from subscribing to newly issued securities that the Company offers to existing shareholders on a pro rata basis, and may result in a dilution of the shareholding of such investors. Furthermore, the Company is not obligated to file for registration of its securities in any other country or jurisdiction outside of Thailand to allow foreign investors the right to subscribe to newly issued securities offered to existing shareholders on a pro rata basis.
The sale of a significant number of the Company’s ordinary shares on the Stock Exchange of Thailand after this initial public offering, or even the anticipation of such sales, may adversely affect the market price of the Company’s ordinary shares. The share price may decline substantially, potentially resulting in losses for investors who purchase the Company’s ordinary shares in this offering, and may also impact the liquidity of the shares in the Stock Exchange. In addition, changes in the shareholding structure may lead to changes in the management structure in line with the investment policies of new investors. Nevertheless, such changes will be carried out with due consideration of the best interests of the Company, and any changes in directors and/or additions of directors, executives, or personnel must be undertaken in compliance with applicable regulations.
The Company discloses information regarding shareholding structure and significant changes fully and in a timely manner to enable investors to appropriately assess potential impacts. The Company operates under the principles of Good Corporate Governance to promote transparency and confidence among security holders. The Company monitors and evaluates potential impacts arising from changes in the shareholding structure in order to prepare proactive measures. The Company promotes continuous communication with security holders and investors to build understanding and reduce concerns that may arise from the sale of shares by major shareholders. Any changes in the management structure that may occur will be undertaken with due consideration of the best interests of the Company and in compliance with applicable regulations, to ensure that management remains stable and consistent.
Unlock full benchmarking
Claim this company to see every KPI your sector qualifies for, from 70+ across the market, benchmarked against sector peers.

